Organizer
The Institute of Medical Science,
The University of Tokyo
6-1, Shirokanedai-4, Minato-ku, Tokyo, Japan,
108-8639 Japan
Congress Secretariat
c/o JTB Communication Design, Inc. JTB Bldg. 6F, 7F
2-1-25 Kyutaromachi, Chuo-ku, Osaka
541-0056, Japan
E-mail: jstct2022@jtbcom.co.jp

Welcome Message

Welcome to the 44th Annual Meeting of the Japanese Society for Transplantation and Cellular Therapy!

Satoshi Takahashi
JSTCT2022 President
Satoshi Takahashi, MD, PhD
Projected Professor,
Division of Clinical Precision Research Platform,
Department of Hematology/ Oncology,
Director,
Adult Hematopoietic Cell Transplant and Cellular Immunotherapy Program,
The Institute of Medical Science, The University of Tokyo

The Japan Society for Hematopoietic Cell Transplantation (JSHCT) has changed its name to the Japanese Society for Transplantation and Cellular Therapy (JSTCT) since early this year, and we are pleased to announce that the first annual meeting after renaming will be held in Yokohama on May 12-14, 2022. We would like to extend a hearty welcome to all our delegates.

The Society was founded in 1978 as the Japanese Society for Bone Marrow Transplantation which has served as an annual forum for researchers and clinicians. At the 18th annual meeting held in 1995 (Tokyo, Meeting president: Professor Shigetaka Asano), the number of abstracts exceeded 200 for the first time, and this trend continued the following year when the name of society was changed to the Japan Society for Hematopoietic Cell Transplantation. The cell source, which had been mainly bone marrow cells, was being applied to peripheral blood stem cells and cord blood, and the research on the aspect of immunotherapy was also in the limelight. At that time, in the discussion on the name of the society in view of the future direction, not the "Hematopoietic Stem Cell Transplantation", but the “Hematopoietic Cell Transplantation” was adopted. It shows the foresight of the leaders at that time, late ’90s. A quarter of a century later, hematopoietic stem cell transplantation is now evolving into cell therapy using stem cells and immune cells, that change has become a reality.

On the other hand, when we look back on our history, I feel that where we are now is still in the process of evolution. Perhaps in the not-too-distant future, a new path toward overcoming intractable diseases will be opened up, and the name of our society may be changed again. By always keeping in mind that we are on the road to evolution, and with an eye on the path of hope for the next generation, There is, interestingly, a custom of attaching a theme to academic meeting in Japan, so, I have chosen the theme of this meeting as “Transplant, Cell Therapy, and Beyond”.

Even in the midst of these changes, the essence of the JSTCT2022 is to provide a forum for the exchange of information among a group of all medical professionals who aim to improve the level of treatment and care using the technologies related to transplantation and cellular therapy. Even in the era of COVID-19 pandemic starting in 2020, there are "comrades" who are devoted to clinical and research activities day and night to relieve the suffering of patients with intractable diseases. In JSTCT2022, we are planning various sessions, projects and events based on the mind of “Transplant, Cell Therapy, and Beyond”. Of course, the safety of our members is directly related to the safety of our patients, so we will be prepared to take flexible measures, such as holding the conference as a hybrid or online, depending on the situation. However, I sincerely hope that in May 2022, all of us will be able to meet in Yokohama, very beautiful city, and exchange the information of our research and clinical work and our friendship.

August, 2021
Page Top